Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

tuximab in combination with docetaxel in advanced breast cancer patients. The results showed that bavituximab achieved the pre-specified stage 1 primary endpoint in this trial. Of 14 evaluable patients, seven achieved partial tumor responses and seven had stable disease at week eight according to RECIST criteria. None showed tumor progression during this period.

-- In July 2008, Peregrine announced that it entered into a five-year contract worth up to $44.4 million to test and develop bavituximab and an equivalent fully human antibody as potential broad spectrum treatments for viral hemorrhagic fever infections. The initial contract was awarded through the Transformational Medical Technologies Initiative of the U.S. Department of Defense's Defense Threat Reduction Agency.

-- In June 2008, Peregrine announced that patient screening and dosing had begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with carboplatin and paclitaxel in patients with the form of lung cancer know as NSCLC, which is the most commonly occurring cancer in both men and women and lacks effective treatment.

-- In March 2008, Peregrine announced a clinical update on its Cotara program for the treatment of glioblastoma multiforme (GBM), covering the first cohort of patients in its dosimetry trial as well as experience to date in an ongoing Phase II safety and efficacy trial. Cotara appeared to be safe and well tolerated in these brain cancer patients. Several patients who are continuing in the trials have already surpassed the expected median survival time for relapsed GBM patients.

-- In February 2008, Peregrine announced that patient dosing had begun in its first Phase II bavituximab trial. This clinical trial is designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

-- In November 2007 at the prestigious AASLD meeting, Peregrine repor
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Calif. , July 30, 2014   ... on the Fully Integrated Lifecycle Mission Support Services ... Space Administration (NASA). Under the terms of the ... Research Center at Moffett Field, Calif. In particular, ... for bioscience flight development projects on the International ...
(Date:7/30/2014)... Vycom announces the addition of Thermax PVC to ... Mutual (FM) 4910 fire propagation and smoke generation criteria ... tools, fume hoods, furniture and cabinetry. These criteria reduce ... used in electronic chip manufacturing. , Flametec ... workability and superior aesthetics. It is available in a ...
(Date:7/30/2014)... COLLEGE PARK, Md. , July 30, 2014 ... with biological components to interrogate biology, but such ... control biology. As such, researchers ... cells for in vitro metabolic engineering ... metabolism on a chip. New devices are envisioned ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... PARK, N.C. and MIAMI, Oct. 13 The Alpha-1 ... grants to study how genetic variations in the alpha-1 ... in people with AAT deficiency. The inherited condition causes ... whether AAT infusion therapy -- known as augmentation therapy ...
... , CHICAGO, Oct. 13 Advanced Life Sciences ... company engaged in the discovery, development and commercialization ... infection, cancer and respiratory diseases, today announced that ... held October 28-29th in San Francisco. , (Logo: ...
... LONDON, October 13 Systagenix Wound Management ... Board, consisting of,a group of multi-disciplinary and highly respected ... which will be led by,Systagenix,s newly appointed Medical Director, ... major specialist organisations and thought leaders in the,wound care ...
Cached Biology Technology:The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 2The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 3The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. 4Advanced Life Sciences to Present at 8th Annual BIO Investor Forum 2Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 2Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 3Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 4Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 5Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care 6
(Date:7/30/2014)... treatment has been shown to relieve patients, pain. ... transmission between the peripheral and central nervous systems, ... Radiation Medicine, Chinese Academy of Medical Sciences, China ... dorsal root ganglia (DRG) to provide relief for ... 14.8, 29.6 MBq) were implanted separately into the ...
(Date:7/30/2014)... of cells types. Researchers would like to understand how to ... that make up the organs and other structures of living ... of sugars that dangle from proteins on surfaces of cells. ... Diego, has created synthetic molecules that can stand in for ... direct the process, they report in the Journal of ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... with the United States Air Force Research Laboratory ... by Binghamton University to ... performance monitoring (HPM). The $425,000 project, with contributions ... packaging firm i3 Electronics, Inc. ( Endicott, ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... Researchers studying a type of cell found in the trillions ... how it responds to brain injury and disease such as ... trigger the processes that underlie how astrocyte cells respond to ... humans, are a type of glial cell that comprise one ...
... 25, 2013 , , , WHEN:               ... 1, 2013 , , , , LOCATION:       ... , , , SPEAKER:        , , , ... Augmented reality (AR) is here to ...
... of regular aerial surveys and genetics data collected by a ... the central Gulf of Maine as a mating ground for ... online in the journal Endangered Species Research . ... one of the most endangered marine mammal species in the ...
Cached Biology News:Key target responsible for triggering detrimental effects in brain trauma identified 2The (Augmented) Reality of the Situation: Emerging Trends and Issues 2The (Augmented) Reality of the Situation: Emerging Trends and Issues 3Are North Atlantic right whales mating in the Gulf of Maine? 2Are North Atlantic right whales mating in the Gulf of Maine? 3